# Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Canonical URL: https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-first-quarter-2026-financial-results-provides-corporate-update-announces-cfo-transition
Ticker: RANI
Company: Rani Therapeutics
Source: Rani Therapeutics
Published: 2026-05-15 20:05 EST
Original Source URL: http://ir.ranitherapeutics.com
## Summary

- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper Høiland as Head of Strategy and Dr.

## Article Body
- Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen – - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer - - Appointed Jesper Høiland as Head of Strategy and Dr.
## Recent Company News
- 2026-07-20 20:05 EST — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) — Source: Rani Therapeutics
- 2026-07-15 12:00 EST — [Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-positive-initial-phase-1a-data-for-rt-114-for-the-tr-e7d21ddc) — Source: Rani Therapeutics
- 2026-07-09 20:05 EST — [Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates](https://biopharmsignal.com/news/RANI/rani-therapeutics-announces-research-and-development-collaboration-with-pegbio-t-5a7630da) — Source: Rani Therapeutics
- 2026-06-29 12:00 EST — [Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer](https://biopharmsignal.com/news/RANI/rani-therapeutics-appoints-nicholas-maestas-as-chief-financial-officer-5b23c7dd) — Source: Rani Therapeutics
- 2026-05-26 12:00 EST — [Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules](https://biopharmsignal.com/news/RANI/rani-therapeutics-holdings-inc-announces-pricing-of-20-0-million-registered-direct-offering-of-class-a-common-stock-priced-at-the-market-under-nasdaq-rules) — Source: Rani Therapeutics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)